The company is likely to be valued ₹1,800-2,000 crore, the people said. KPMG is advising the promoters on the stake sale. BL Lifesciences, a fourth-generation family-owned business, primarily focuses on products for cardiac surgery, critical care, interventional cardiology, anaesthesia and surgical care.